369 related articles for article (PubMed ID: 10956636)
1. Inhibition of angiogenesis decreases alveolarization in the developing rat lung.
Jakkula M; Le Cras TD; Gebb S; Hirth KP; Tuder RM; Voelkel NF; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2000 Sep; 279(3):L600-7. PubMed ID: 10956636
[TBL] [Abstract][Full Text] [Related]
2. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure.
Le Cras TD; Markham NE; Tuder RM; Voelkel NF; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2002 Sep; 283(3):L555-62. PubMed ID: 12169575
[TBL] [Abstract][Full Text] [Related]
3. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor.
Tang JR; Markham NE; Lin YJ; McMurtry IF; Maxey A; Kinsella JP; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2004 Aug; 287(2):L344-51. PubMed ID: 15064225
[TBL] [Abstract][Full Text] [Related]
4. Early inhaled nitric oxide treatment decreases apoptosis of endothelial cells in neonatal rat lungs after vascular endothelial growth factor inhibition.
Tang JR; Seedorf G; Balasubramaniam V; Maxey A; Markham N; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2007 Nov; 293(5):L1271-80. PubMed ID: 17827251
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats.
Kunig AM; Balasubramaniam V; Markham NE; Morgan D; Montgomery G; Grover TR; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2005 Oct; 289(4):L529-35. PubMed ID: 15908474
[TBL] [Abstract][Full Text] [Related]
6. Abnormal lung growth and the development of pulmonary hypertension in the Fawn-Hooded rat.
Le Cras TD; Kim DH; Gebb S; Markham NE; Shannon JM; Tuder RM; Abman SH
Am J Physiol; 1999 Oct; 277(4):L709-18. PubMed ID: 10516211
[TBL] [Abstract][Full Text] [Related]
7. Impaired alveolarization and intra-uterine growth restriction in rats: a postnatal genome-wide analysis.
Zana-Taieb E; Pham H; Franco-Montoya ML; Jacques S; Letourneur F; Baud O; Jarreau PH; Vaiman D
J Pathol; 2015 Feb; 235(3):420-30. PubMed ID: 25347958
[TBL] [Abstract][Full Text] [Related]
8. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
Roman CD; Choy H; Nanney L; Riordan C; Parman K; Johnson D; Beauchamp RD
J Surg Res; 2002 Jun; 105(1):43-7. PubMed ID: 12069500
[TBL] [Abstract][Full Text] [Related]
10. Inhaled nitric oxide improves lung structure and pulmonary hypertension in a model of bleomycin-induced bronchopulmonary dysplasia in neonatal rats.
Tourneux P; Markham N; Seedorf G; Balasubramaniam V; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2009 Dec; 297(6):L1103-11. PubMed ID: 19837849
[TBL] [Abstract][Full Text] [Related]
11. Expression of angiogenic factors and their receptors in postnatal mouse developing lung.
Tsao PN; Li H; Wei SC; Ko ML; Chou HC; Hsieh WS; Hsieh FJ
J Formos Med Assoc; 2004 Feb; 103(2):137-43. PubMed ID: 15083245
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension.
Taraseviciene-Stewart L; Kasahara Y; Alger L; Hirth P; Mc Mahon G; Waltenberger J; Voelkel NF; Tuder RM
FASEB J; 2001 Feb; 15(2):427-38. PubMed ID: 11156958
[TBL] [Abstract][Full Text] [Related]
13. Regulation and action of angiogenic factors in the primate ovary.
Stouffer RL; Martínez-Chequer JC; Molskness TA; Xu F; Hazzard TM
Arch Med Res; 2001; 32(6):567-75. PubMed ID: 11750732
[TBL] [Abstract][Full Text] [Related]
14. Neonatal dexamethasone treatment increases the risk for pulmonary hypertension in adult rats.
le Cras TD; Markham NE; Morris KG; Ahrens CR; McMurtry IF; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2000 Apr; 278(4):L822-9. PubMed ID: 10749760
[TBL] [Abstract][Full Text] [Related]
15. Expression of vascular endothelial growth factor and Flk-1 in developing and glucocorticoid-treated mouse lung.
Bhatt AJ; Amin SB; Chess PR; Watkins RH; Maniscalco WM
Pediatr Res; 2000 May; 47(5):606-13. PubMed ID: 10813585
[TBL] [Abstract][Full Text] [Related]
16. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
Laird AD; Christensen JG; Li G; Carver J; Smith K; Xin X; Moss KG; Louie SG; Mendel DB; Cherrington JM
FASEB J; 2002 May; 16(7):681-90. PubMed ID: 11978732
[TBL] [Abstract][Full Text] [Related]
17. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
18. Early abnormalities of pulmonary vascular development in the Fawn-Hooded rat raised at Denver's altitude.
Le Cras TD; Kim DH; Markham NE; Abman AS
Am J Physiol Lung Cell Mol Physiol; 2000 Aug; 279(2):L283-91. PubMed ID: 10926551
[TBL] [Abstract][Full Text] [Related]
19. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Ning S; Laird D; Cherrington JM; Knox SJ
Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
[TBL] [Abstract][Full Text] [Related]
20. General aspects of anti-angiogenesis and cancer therapy.
Zogakis TG; Libutti SK
Expert Opin Biol Ther; 2001 Mar; 1(2):253-75. PubMed ID: 11727534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
